Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780127 | 1.00 | IDO1 (0.43) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL23780079 | 0.98 | IDO1 (0.43) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL31109435 | 0.98 | IDO1 (0.43) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL31109474 | 0.92 | IDO1 (0.44) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL23780153 | 0.92 | IDO1 (0.44) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL23780145 | 0.90 | IDO1 (0.44) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL31109391 | 0.90 | IDO1 (0.44) | IDO1MAPTALOX15TMEM97CFD | |
| SCHEMBL23780146 | 0.89 | IDO1 (0.41) | IDO1KDM4E | |
| SCHEMBL31109345 | 0.89 | IDO1 (0.41) | IDO1KDM4E | |
| SCHEMBL23780243 | 0.88 | IDO1 (0.39) | IDO1MAPTALOX15TMEM97CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | claimed |
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885MAPT 2054/4885ALOX15 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.